These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24599112)

  • 21. Development of
    Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
    Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SPECT-OPT multimodal imaging enables accurate evaluation of radiotracers for β-cell mass assessments.
    Eter WA; Parween S; Joosten L; Frielink C; Eriksson M; Brom M; Ahlgren U; Gotthardt M
    Sci Rep; 2016 Apr; 6():24576. PubMed ID: 27080529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys
    Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L
    Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
    Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
    Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas.
    Souza F; Freeby M; Hultman K; Simpson N; Herron A; Witkowsky P; Liu E; Maffei A; Harris PE
    Curr Med Chem; 2006; 13(23):2761-73. PubMed ID: 17073627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET/MRI enables simultaneous
    Michelotti FC; Bowden G; Küppers A; Joosten L; Maczewsky J; Nischwitz V; Drews G; Maurer A; Gotthardt M; Schmid AM; Pichler BJ
    Theranostics; 2020; 10(1):398-410. PubMed ID: 31903128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of [18F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass.
    Wang Y; Lim K; Normandin M; Zhao X; Cline GW; Ding YS
    Nucl Med Biol; 2012 Feb; 39(2):167-76. PubMed ID: 22033026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog.
    Reiner T; Thurber G; Gaglia J; Vinegoni C; Liew CW; Upadhyay R; Kohler RH; Li L; Kulkarni RN; Benoist C; Mathis D; Weissleder R
    Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12815-20. PubMed ID: 21768367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
    Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
    Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (111)In-exendin uptake in the pancreas correlates with the β-cell mass and not with the α-cell mass.
    Brom M; Joosten L; Frielink C; Boerman O; Gotthardt M
    Diabetes; 2015 Apr; 64(4):1324-8. PubMed ID: 25409700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Kataoka HU; Takatsuka T; Miyamoto S; Sasaki M; Kajitani N; Nishishita S; Sarai K; Hirota D; Sato C; Ogawa D; Makino H
    Diabetologia; 2011 Apr; 54(4):965-78. PubMed ID: 21253697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta cell specific probing with fluorescent exendin-4 is progressively reduced in type 2 diabetic mouse models.
    Lehtonen J; Schäffer L; Rasch MG; Hecksher-Sørensen J; Ahnfelt-Rønne J
    Islets; 2015; 7(6):e1137415. PubMed ID: 26963143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic β-cell destruction induced by encephalomyocarditis virus.
    Sano H; Terasaki J; Mishiba Y; Imagawa A; Hanafusa T
    Biochem Biophys Res Commun; 2011 Jan; 404(3):756-61. PubMed ID: 21144822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
    Xu G; Stoffers DA; Habener JF; Bonner-Weir S
    Diabetes; 1999 Dec; 48(12):2270-6. PubMed ID: 10580413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents.
    Gotthardt M; Lalyko G; van Eerd-Vismale J; Keil B; Schurrat T; Hower M; Laverman P; Behr TM; Boerman OC; Göke B; Béhé M
    Regul Pept; 2006 Dec; 137(3):162-7. PubMed ID: 16930741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with
    Hamamatsu K; Fujimoto H; Fujita N; Murakami T; Shiotani M; Toyoda K; Inagaki N
    Sci Rep; 2019 Dec; 9(1):18338. PubMed ID: 31797889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.
    Christ E; Wild D; Ederer S; Béhé M; Nicolas G; Caplin ME; Brändle M; Clerici T; Fischli S; Stettler C; Ell PJ; Seufert J; Gloor B; Perren A; Reubi JC; Forrer F
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):115-22. PubMed ID: 24622317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
    Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
    J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs.
    Rydén A; Nyman G; Nalin L; Andreasson S; Velikyan I; Korsgren O; Eriksson O; Jensen-Waern M
    Nucl Med Biol; 2016 Jul; 43(7):397-402. PubMed ID: 27179248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.
    Normandin MD; Petersen KF; Ding YS; Lin SF; Naik S; Fowles K; Skovronsky DM; Herold KC; McCarthy TJ; Calle RA; Carson RE; Treadway JL; Cline GW
    J Nucl Med; 2012 Jun; 53(6):908-16. PubMed ID: 22573821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.